Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-09-26T00:16:05.271Z.
Calculation as of: 2026-09-26T00:16:05.271Z.
Quote observation: 2026-09-25T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d36a9ef3dd00a3b0176393925906ed0ad09061a29621a98fe511a29c7f47a262
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$30.55B
EV/FCF Ratio
37.74x
TTM Avg
34.44x
3Y Avg
33.39x
5Y Avg
37.69x
Market Cap
$34.25B
EV/FCF Ratio
62.32x
TTM Avg
130.42x
3Y Avg
464.56x
5Y Avg
464.56x
Market Cap
$30.10B
EV/FCF Ratio
42.55x
TTM Avg
29.47x
3Y Avg
27.72x
5Y Avg
27.20x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ResMed Inc. (RMD) | $32.20B | N/A | N/A | N/A | N/A |
| DexCom, Inc. (DXCM)vs › | $32.69B | 23.47x | 27.78x | 58.70x | 164.13x |
| Alcon Inc. (ALC)vs › | $31.44B | 21.02x | 25.90x | 44.12x | 95.67x |
| Biogen Inc. (BIIB)vs › | $33.63B | 15.09x | 13.15x | 19.83x | 20.74x |
| Mettler-Toledo International Inc. (MTD)vs › | $30.55B | 37.74x | 34.44x | 33.39x | 37.69x |
| Centene Corp. (CNC)vs › | $30.53B | 2.51x | 6.56x | 24.55x | 18.52x |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $34.25B | 62.32x | 130.42x | 464.56x | 464.56x |
| GE HealthCare Technologies Inc. (GEHC)vs › | $30.10B | 42.55x | 29.47x | 27.72x | 27.20x |
| Zoetis Inc. (ZTS)vs › | $29.79B | 15.87x | 24.44x | 38.29x | 46.28x |
| Medline Inc. (MDLN)vs › | $29.34B | 29.55x | 25.69x | 25.69x | 25.69x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute